The use of immunocompromised animals as models for human septic shock

Shock

Volumn 24, Issue SUPPL. 1, 2005, Pages 64-70

  Opal, Steven M ^a   Cross, Alan S ^b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b NONE

Author keywords

Immunocompromised host; SCID Hu mice; Sepsis; Septic shock

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT; NEW DRUG;

ADAPTIVE IMMUNITY; ANIMAL MODEL; C3H MOUSE; CLEARANCE; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE RESPONSE; INNATE IMMUNITY; MICROBIAL CLEARANCE; MOUSE STRAIN; NONHUMAN; REVIEW; SCID HU MOUSE; SCID MOUSE; SEPSIS; SEPTIC SHOCK;

AGED; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, INNATE; IMMUNITY, NATURAL; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, SCID; MIDDLE AGED; MYELOABLATIVE AGONISTS; SHOCK, SEPTIC;

EID: 33646787140     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000191335.93412.3e     Document Type: Review

References (72)

1. Quartin AA, Schein MH, Kett DH, Peduzzi PN, for the Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group: Magnitude and duration of the effects of sepsis on survival. J Am Med Assoc 277:1058-1063, 1997.
2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554, 2003.
3. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, Le Gall JR: Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28:108-121, 2002.
4. Ely EE, Laterre P-F, Angus D, Helterbrand JD, Levy H, Dhainaut J-F, Vincent J-L, Macias WL: Bernard GR for the PROWESS Investigators. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:12-18, 2003.
5. Angus DC, Zwirble-Linde WT, Lidicker J, Clermont MA, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States. Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
6. Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K: Lipopolysaccharide- induced lethality and cytokine production in aged mice. Infect Immun 64:769-774, 1996.
7. Yamamoto K, Shimokawa T, Yi H, Isobe K-I, Kojima T, Loskutoff DJ, Saito H: Aging accelerates endotoxin-induced thrombosis. Am J Pathol 161:1805-1814, 2002.
8. Cohen HJ, Harris T, Pieper CF: Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly. Am J Med 114:180-187, 2001.
9. Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD: Hypercoagulability in centenarians: the paradox of successful aging. Blood 85:3144-3149, 1995.
10. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J, Fried LP for the Cardiovascular Health Study Investigators: Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities. Arch Intern Med 162:2333-2341, 2002.
11. Pittet D, Thiívent B, Wenzel RP, Li N, Gurman G, Suter PM: Importance of preexisting co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med 19:265-272, 1993.
12. Cross AS, Opal SM: A new paradigm for the treatment of sepsis: is it time to consider combination therapy? Ann Intern Med 138:502-505, 2003.
13. Opal SM, Cross AS: The use of immunocompromised animals in sepsis research. Sepsis 2:235-242, 1999.
14. Hotchkiss RS, Karl IE: The pathology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
15. Beutler B, Poltorak A: The search for LPS: 1991-1998. J Endocr Res 6:269-293, 2000.
16. Opal SM, Huber CE: The Toll-like receptors and their role in septic shock. Crit Care 6:125-136, 2002.
17. Eichacker PQ, Parent C, Kalil A, Esposito C, Xizhong C, Banks SM, Gerstenberger EP, Fitz Y, Danner RL, Natanson C: Risk and the efficacy of anti-inflammatory agents. Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 166:1197-1205, 2002.
18. Rachmilewitz D, Karmeli F, Takabayashi K, Hayashi T, Leider-Trejo L, Lee J, Leoni LM, Raz E: Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122:1428-1441, 2002.
19. Hacker G, Redecke V, Hacker H: Activation of the immune system by bacterial CpG-DNA. Immunology 105:245-251, 2002.
20. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B: Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 165:4537-4543, 2000.
21. Heil F, Hemmi H, Hochrein H: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1528, 2004.
22. Patel M, Kashavarzian A, Kottapalli V, et al.: Human neutrophil functions are inhibited in vitro by clinically relevant ethanol concentrations. Alcohol Clin Exp Res 20:275-283, 1996.
23. Joshi VD, Kalvakolanu DV, Hebel JR, Hasday JD, Cross AS: Role of caspase 1 in murine antibacterial host defenses and lethal endotoxemia. Infect Immun 70:6896-6903, 2002.
24. Joshi VD, Kalvakolanu DV, Hasday JD, Hebel RJ, Cross AS: IL-18 levels and the outcome of innate immune response to lipopolysaccharide: importance of a positive feedback loop with caspase-1 in IL-18 expression. J Immunol 169:2536-2544, 2002.
25. Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709, 2001.
26. Annane D, Séville V, Charpentier C, Ballaert P-E, François B, Korach J-M, Capallier G, Cohen Y, Azomlay E, Traché G, Chaumet RF, Faut P, Bellisant E: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 288:862-871, 2002.
27. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368-1377, 2001.
28. Schneider C, von Aulock S, Siegfried Z, Schinkel C, Hartung T, Faist E: Perioperative recombinant human granulocyte colony-stimulating factor (filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 239:75-81, 2004.
29. Ellis M, Zwaan F, Hedstrom V, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B: Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet 361:275-280, 2003.
30. Piper RD, Cook DJ, Bone RC, Sibbald WJ: Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 24:2059-2070, 1996.
31. Howard M, Muchamuel T, Andrade S, Memon S: Interleukin-10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208, 1993.
32. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RF, Standiford TJ: Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 155:722-729, 1995.
33. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P: Pretreatment with recombinant murine tumor necrosis factor α/cachectin in murine interleukin-1α protects mice from lethal bacterial infection. J Exp Med 169:2021-2027, 1989.
34. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64:4733-4738, 1996.
35. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S: Divergent efficacy of antibody to tumor necrosis factor-α and intravascular and peritonitis models of sepsis. J Infect Dis 163:83-88, 1991.
36. Opal SM, Cross AS: Clinical trials for sepsis: past failures and future hopes. Infect Dis Clinic North Am 13:285-298, 1999.
37. Cross AS, Opal SM, Sadoff JC, Gemski P: Choice of bacteria in animal sepsis models. Infect Immun 61:2741-2747, 1993.
38. Esmon CT: Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 32:S219-S222, 2004.
39. Ely EW, Laterre PF, Angus D, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Marcias WL, Bernard GR, for the PROWESS Investigators: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:12-19, 2003.
40. Yeung RS, Penninger J, Mak TW: Genetically modified animals and immunodeficiency. Curr Opin Immunol 5:585-594, 1993.
41. Ohsugi T, Kiuchi Y, Shimoda K: Translocation of bacteria from the gastrointestinal tract in immunodeficient mice. Lab Anim 30:46-50, 1996.
42. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, Bravo R: Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of Re1B, a member of the NF-κB family. Cell 80:331-340, 1995.
43. Shockett P, Difilippantonio M, Hellman N, Schatz DG: A modified tetracycline-regulated system provides autoregulator inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 92:6522-6526, 1995.
44. MacMicking J, Xie QM, Nathan C: Nitric oxide and macrophage function. Annu Rev Microbiol 15:323-350, 1997.
45. Yan L, Vandivier RW, Suffredini AF, Danner RL: Human polymorphonuclear leukocytes lack detectable nitric oxide synthase activity. J Immunol 153:1825-1834, 1994.
46. Gross SS, Kilbourn RG, Griffith OW: NO in septic shock: good, bad, or ugly? Lessons learned from iNOS knockouts. Trends Microbiol 4:47-49, 1996.
47. H1 cell development. Science 271:984-987, 1996.
48. Güler ML, Jacobson NG, Gulber U, Murphy KM: T cell genetic background determines maintenance of IL-12 signaling, effects of BALB/c and B10.D2 T helper cell type 1 phenotype development. J Immunol 159:1767-1774, 1997.
49. Qin L, Quinlan WM, Doyle NA, Graham L, Sligh JE, Takei F, Beaudet AL, Doerschuk CM: The roles of CD11/CD18 and ICAM-1 in acute Pseudomonas aeruginosa-induced pneumonia in mice. J Immunol 157:5016-5021, 1996.
50. Falk LA, McNally R, Perera P-Y, Vogel SN: LPS-inducible responses in severe combined immunodeficiency (SCID) mice. J Endotoxin Res 2:273-280, 1995.
51. Opal SM, Cohen J: Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis. Crit Care Med 27:1608-1616, 1999.
52. Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA: Characterization of early cytokine responses and an interleukin (IL)-6-dependent pathway of endogenous glucocorticoid induction during murine cytomegalovirus infection. J Exp Med 185:1185-1192, 1997.
53. Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, Parlato S, Belardelli F: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J Exp Med 198:361-367, 2003.
54. Uckun FM, Rajamohan F, Pendergrass S, Ozer Z, Waurzyniak B, Mao C: Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 47:1052-1061, 2003.
55. d allele: analysis of chromosome 4 markers surrounding the Lps gene. Infect Immun 62:4454-4459, 1994.
56. Echtenacher B, Freudenberg MA, Jack RS, Manuel DN: Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect Immun 69:7271-7276, 2001.
57. Sorensen TIA, Nielsen GG, Andersen PK, Teasdale TW: Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 318:727-732, 1988.
58. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, Levin M: A mutation in the interferon-γ receptor gene and susceptibility to mycobacterial infection. N Engl J Med 335:1941-1949, 1996.
59. Beutler B: Science review: key inflammatory and stress pathways in critical illness. Crit Care 7:39-46, 2003.
60. Lorenz E, Mira J-P, Frees KG, Schwartz DA: Relevance of mutations in the TLR4-receptor in patients with gram-negative septic shock. Arch Intern Med 162:1028-1031, 2002.
61. Opal SM, Cross AS, Jhung JW, Young LD, Palardy JE, Parejo NA, Donsky C: Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J Infect Dis 173:1415-1421, 1996.
62. Russel DA, Tucker KK, Kinookoswong N, Thompson RC, Kohno T: Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival in organ function. J Infect Dis 171:1528-1538, 1995.
63. Opal SM, Jhung J, Keith JC Jr, Goldman SJ, Palardy JE, Parejo N: The additive effects of recombinant human interleukin-11 and granulocyte-colony stimulating factor in experimental gram-negative sepsis. Blood 93:1-7, 1999.
64. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudskk, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A: P55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. J Am Med Assoc 277:1531-1538, 1997.
65. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R: Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. J Am Med Assoc 273:934-941, 1995.
66. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 334:1697-1702, 1996.
67. Cohen J, Abraham E: Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock. J Infect Dis 180:116-121, 1999.
68. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, Banks SM, Eichacker PQ: G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 159:1377-1382, 1999.
69. Duritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ, Mallon KP, Rich WJ, Jacobson MA: Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS 12:65-74, 1998.
70. Cheng AC, Stephens DP, Currie BJ: Granulocyte colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst Rev 4:2003.
71. Opal SM, Keith JC Jr, Jhung J, Palardy JE, Parejo N, Marchese E, Maganti V: Orally administered recombinant human interleukin-11 is protective in experimental neutropenic sepsis. J Infect Dis 187:70-76, 2003.
72. Opal SM, Jhung J, Keith J Jr, Palardy JE, Parejo N, Schaub J: Human recombinant interleukin-11 in the treatment of immunocompromised animals with experimental Pseudomonas aeruginosa sepsis. J Infect Dis 178:1205-1208, 1998.